# Table of Contents

**Table of Contents**  

I. Clinical Presentation  
   - Introduction 3  
   - Symptoms 3  
   - Signs 5  
   - Complications and Clinical Outcomes 5  
   - Risk Factors for Disease Severity 5  
   - Risk Factors Associated with In-Hospital Death 6  
   - References 8  

II. Testing 9  
   - Introduction 9  
   - Who to test 9  
   - How to test 11  
   - About the Test 12  
   - Test results 13  
   - References 14  

III. Personal Protective Equipment (PPE) 15  
   - Summary 15  
   - Minimizing the need for PPE 16  
   - Rational use of PPE 16  
   - How to don and doff PPE 16  
   - Code Blue Protocol PPEs 17  
   - Aerosol-generating procedures 17  
   - Modes of transmission 18  

IV. Guidelines for ICU/HAU Consultation 20  
   - Guidelines 20  
   - Predictors of Poor Outcome 20  
   - Code Blue Planning 20  
   - VCH/PHC CPR Protocol 21  
   - References 21  

V. Supportive Measures 21  
   - Guiding Principle 21
General 21
Monitoring 22
Hypoxemic Respiratory Failure 22
Care for Patients Not Suitable For Critical Care 23
Hypotension / Shock 23
Hypertension, Heart Failure 23
Intubation & Ventilation Strategies4,6,7 23
Arrhythmia, Cardiac Injury 24
Hepatitis 24
References & Resources 25

VI. PoCUS Guidelines 25
Main message 25
Indications for POCUS 25
Contraindications for POCUS during COVID pandemic 25
POCUS providers 26
POCUS machines 26

VII. Treatment 26
Standard Treatment 26
Therapeutic Agents Under Investigation 27
  Favipiravir 27
  Hydroxychloroquine and Chloroquine 27
  Tocilizumab 29
  Remdesivir 31
  Lopinivir/ritonivir 32
Other treatment-related information 32
  NSAID use 32
  ACEi/ARB use 32
References 35

VIII. Supplementary Materials 37
End-of-life Care in COVID 37
Hospital Specific Links 38
I. Clinical Presentation

Ashley Yip, Abdulazi Alshaibi, Dana Mohammad, Curtis Williams. Last updated Mar 20, 2020

Introduction

- Clinical presentation is non-specific and may range from asymptomatic to severe pneumonia and death
- Symptoms and signs typically develop 5-6 days after infection (mean incubation period 5-6 days, range 1-14 days)\(^1\)
- 97.5% of patients develop symptoms within 11.5 days of infection
- Viral shedding persisted for a median of 20 days in survivors and persisted until death in non-survivors.\(^2\)
- Majority have mild disease and recover
  - 80% of laboratory confirmed patients have mild to moderate disease
  - 13.8% have severe disease (dyspnea, respiratory rate > 30/minute, O₂ saturation < 93%, PaO₂/FiO₂ ratio < 300 and/or lung infiltrates > 50% of lung field within 24-48 hours)
  - 6.1% are critical (respiratory failure, septic shock, and/or multiple organ dysfunction/failure)

Symptoms

Typically derived from inpatient cohorts:

- Dry cough (67.7%)
- Fatigue (23-38.1%)
- Sputum production (23-33.4%)
- Shortness of breath (18.6%)
- Sore throat (13.9%)
- Headache (13.6%)
- Myalgia or arthralgia (14.8-15%)
- Chills (11.4%)
- Nausea or vomiting (4-5%)
- Nasal congestion (4.8%)
- Diarrhea (3.7-5%)
- Hemoptysis (0.9%)
- Conjunctival congestion (0.8%)

Notes:
- Fever is the most common symptom, but only present in 48% on admission - will typically develop during admission in 88%
- Patients can sometimes present with only GI symptoms
Asymptomatic patients 1,2,3

- There is little literature on mass screenings and identifying patients with asymptomatic infections
- One study looked at the Princess cruise quarantined in Japan. Of the 3711 patients on the cruise, 3063 were tested (Mizumoto et al, EuroSurveillance March 2020)
  - Through mathematical analysis, they believe that about **18% were asymptomatic**

---

**Table of Symptoms near the time of presentation in various cohorts**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Constitutional</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>473/1081 (43%)</td>
<td>18/21 (86%)</td>
<td>46/52 (88%)</td>
<td>82/99 (83%)</td>
<td>40/41 (98%)</td>
<td>48/62 (77%)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>164/1081 (15%)</td>
<td>6/52 (12%)</td>
<td>11/99 (11%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>150/1081 (14%)</td>
<td>2/21 (10%)</td>
<td>8/52 (6%)</td>
<td>8/99 (8%)</td>
<td>2/38 (8%)</td>
<td>21/62 (34%)</td>
</tr>
<tr>
<td>Upper respiratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhinorrhea</td>
<td>53/1081 (5%)</td>
<td>5/21 (24%)</td>
<td>3/52 (6%)</td>
<td>4/99 (4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sore throat</td>
<td>153/1081 (14%)</td>
<td></td>
<td></td>
<td>5/99 (5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower respiratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>205/1081 (19%)</td>
<td>9/21 (43%)</td>
<td>33/52 (64%)</td>
<td>31/99 (31%)</td>
<td>22/40 (55%)</td>
<td>2/62 (3%)</td>
</tr>
<tr>
<td>Chest tightness</td>
<td>5/21 (24%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>745/1081 (68%)</td>
<td>15/21 (71%)</td>
<td>40/52 (77%)</td>
<td>81/99 (82%)</td>
<td>31/41 (76%)</td>
<td>50/62 (81%)</td>
</tr>
<tr>
<td>Sputum</td>
<td>370/1081 (34%)</td>
<td></td>
<td></td>
<td>11/39 (28%)</td>
<td>35/62 (56%)</td>
<td></td>
</tr>
<tr>
<td>Hemoptysis</td>
<td>10/1081 (1%)</td>
<td></td>
<td></td>
<td>2/39 (5%)</td>
<td>2/62 (3%)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea/Vomiting</td>
<td>55/1081 (5%)</td>
<td>2/21 (10%)</td>
<td>2/52 (6%)</td>
<td>1/99 (1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>42/1081 (4%)</td>
<td>1/21 (5%)</td>
<td>2/99 (2%)</td>
<td>1/38 (3%)</td>
<td>3/62 (8%)</td>
<td></td>
</tr>
</tbody>
</table>

### The symptoms of coronavirus disease [COVID-19]

The most common signs and symptoms of 55,924 laboratory confirmed cases of COVID-19, reported from China in the period up to February 22, 2020

- Fever
- Dry cough
- Fatigue
- Sputum production
- Shortness of breath
- Muscle pain or joint pain
- Sore throat
- Headache
- Chills
- Nausea or vomiting
- Nasal congestion
- Diarrhea

Many of the most common symptoms are shared with those of the flu or cold. So it is also good to know which common symptoms of the flu or the common cold are not symptoms of COVID-19. COVID-19 infection seems to rarely cause a runny nose.

Signs

- Vitals
  - Fever (temperature $\geq 37.3$ C) (87.9-94%)$^{1,2}$
  - Moderate hypoxemia
  - Respiratory rate $\geq 24$ breaths per minute (29%)$^2$
  - Heart rate $\geq 125$ beats per minute (1%)$^2$
- Physical examination$^4$
  - Throat congestion (1.7%)
  - Tonsil swelling (2.1%)
  - Enlargement of lymph nodes (0.2%)
  - Rash (0.2%)

Complications and Clinical Outcomes

- Wang D et al Wuhan, China (138 patients hospitalized with COVID-19 pneumonia)
  complications included:$^5$
  - Shock (8.7%)
  - Acute cardiac injury (7.2%)
  - Arrhythmia (16.7%)
  - ARDS (19.6% of all patients and 61.1% of patients requiring ICU admission)
  - AKI (3.6%)
- Guan et al China (1099 patients COVID-19 confirmed +) outcomes:$^4$
  - The median duration of hospitalization, if required, was 12 days.
  - Oxygen therapy was required in 41.3% of patients.
  - ICU admission in 5% of patients.
  - Non-invasive mechanical ventilation in 5.1% of patients.
  - Invasive Mechanical ventilation in 2.3% of patients.
  - Death in 1.4% of patients

- Cytokine storm syndromes$^{12}$
  - A subset of patients with severe COVID-19 disease found to have a cytokine profile that resembles secondary haemophagocytic lymphohistiocytosis (sHLH)
  - Patients have increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α
  - Subset of patients with hyperinflammation may benefit from immunosuppression

Risk Factors for Disease Severity

- Higher D-dimer and more severe lymphopenia associated with mortality
- Higher neutrophil:lymphocyte ratio in more severe cases (>5)
- A high procalcitonin or significant change may indicate bacterial superinfection
Risk Factors Associated with In-Hospital Death

- Older age
- Higher SOFA scores
- D-Dimer >1μg/mL
- Cardiovascular diseases
- Secondary infection
- Elevated inflammatory indicators (Ferritin and IL-6)

Laboratory Findings

- CBC
  - Normal WBC 4-10 x 10^9/L (62%)^2
  - Lymphopenia < 0.8 x 10^9/L (IQR 0.6-1.1) (40-70.3%)^2,^5
  - Leukopenia (33.7%)^4
  - Anemia (15%)^2
  - Mild thrombocytopenia < 100 (7%)^2

- Prolonged PTT (30-58%)
  - 13.0 seconds (IQR 12.3-13.7)^5

- LFTs
  - ALT > 40 U/L (31%)^2

- Elevated LDH (39.9-67%)
  - 261 U/L (IQR 182-403)^2,^5

- ABG
  - Mild acidosis
  - Normal lactate
  - Severe base deficit

- CRP
  - Average 33 in non-severe, 58 in more severe^6

- Serum ferritin
  - > 300 ug/L (80%)^2

- CK
  - > 185 (13%)^2

- IL-6
  - 7.4 pg/mL (5.3 - 10.8 pg/mL)^2
Imaging Findings

- **Chest x-ray**
  - Features on chest x-ray
    - Bilateral patchy infiltrates
    - Gravitational distribution
    - Asymmetry if bacterial super-infection
  - **NOTE:**
    - *Almost 50% of non-severe patients and almost 25% of severe patients had normal x-rays*
    - No CT abnormalities were noted on initial presentation in 2.9% of the patients with severe disease and in 17.9% of those with nonsevere disease

- **CT chest**
  - Features on CT chest
    - Ground-glass opacities (GGO) (86.1%)
    - Mixed GGO and consolidation (64.4%)
    - Vascular enlargement in the lesion (71.3%)
    - Tract bronchiectasis (52.5%)
    - Peripheral distribution (87.1%)
    - Bilateral involvement (82.2%)
    - Lower lung predominant (54.5%)
    - Multifocal (54.5%)
  - CT evidence of viral pneumonia may precede RT-PCR test results

- **COVID-19 Radiology Database**
Lung ultrasound - DO NOT USE PoCUS UNNECESSARILY - SEE PoCUS GUIDELINES

- Features on lung ultrasound
  - Thickening of pleural line with pleural line irregularity
  - B lines (focal, multifocal and confluent)
  - Consolidations (multifocal small, non-translobar, translobar with occasional mobile air bronchograms)
  - Pleural effusions are uncommon

- Clinical application
  - Focal B lines are main feature in early stage and mild infection
  - Alveolar interstitial syndrome is main feature in progressive stage and critically ill patients
  - A lines in convalescence
  - Pleural line thickening with uneven B lines in pulmonary fibrosis
  - Pattern 1: diffuse b-line profile, responds well to PEEP
  - Pattern 2: basal PLAPs points showing consolidation/parapneumonic effusions/atelectasis where front areas ventilated, rear areas are aтелектатич и responsive to pronation
  - Useful in evaluating effect of high PEEP and managing recruitment maneuvers

References

6. Chuan Qin, MD, PhD, Luoqi Zhou, MD, Ziwei Hu, MD, Shuqi Zhang, MD, PhD, Sheng Yang, MD, Yu Tao, MD, PhD, Cuihong Xie, MD, PhD, Ke Ma, MD, PhD, Ke Shang, MD, PhD, Wei Wang, MD, PhD, Dai-Shi Tian, MD, PhD, Dysregulation of immune response in patients with

---

**https://www.sirm.org/category/senza-categoria/covid-19/**
II. Testing

Gurmeet Sohi, Hiten Naik; Last updated Mar 20, 2020

Introduction

The provincial guidelines around testing have been changing. This section will provide some guidance on which patients should be tested and when and where healthcare providers should be tested. Currently, the BC Center for Disease Control has decided the following populations be tested:

1. Hospitalized, or likely to be hospitalized
2. Health care workers
3. Residents of long term care facilities
4. Part of an investigation of a cluster of outbreak

Who to test

The BC COVID-19 Symptom Self Assessment Tool is available to guide patients and health care workers whether they should get tested.

- Patients: Hospitalized, or likely to be hospitalized
Any patient with an influenza-like illness (ILI) who you order an influenza swab on will automatically be tested for COVID-19 at all locations. The specific clinical presentations required for testing varies at the three sites but the presence of fever, cough and respiratory symptoms that cannot be managed at home warrant testing. The site specific criteria are as follows:

- **SPH:** Fever (temp > 37.5 or clinical judgment) or new difficulty breathing or cough
  [Link](https://drive.google.com/file/d/1edSrNBTq89K7pVcmcEnUgrQQjTPMDjvr/view?usp=sharing)
- **VGH:** Fever, respiratory symptoms (new or worsening cough, sore throat or sneezing), or shortness of breath/difficulty breathing
- **RCH:** Fever, respiratory symptoms and radiographic evidence of pneumonia. Testing can be considered for GI symptoms if there is no other clear cause or atypical presentations in the elderly such as delirium or acute functional decline

- **Health care workers**
  If you are feeling unwell, please let your team and the CMR at your site know **immediately** and do not present to work.
  The following categories of health care workers require testing:
  - Symptomatic health care workers - the definition of symptomatic varies between the sites - please refer to the site specific documents for most updated criteria.
    - **SPH:** Fever +/- cough or 2 of the following: fever, cough, shortness of breath, diarrhea, fatigue, malaise, myalgia or rhinorrhea. Travel or known exposure is not required and asymptomatic patients are not screened.
      [Link](https://drive.google.com/file/d/1edSrNBTq89K7pVcmcEnUgrQQjTPMDjvr/view?usp=sharing)
    - **VGH:** Contact with a confirmed or probable case of CoVID19 OR fever >/= 37.5 OR New cough OR Shortness of breath OR other concerning clinical symptoms based on clinical judgement
      [Link](https://drive.google.com/file/d/1LKAuC9huTfGhyXKdJ-BWLlhwITCvTiKQ/view?usp=sharing)
    - **RCH:** Health care workers with confirmed COVID-19 who require a negative test after symptom resolution to return to work.

Where can healthcare workers be tested?

The recommendations for site-specific testing are summarized here but please refer to the respective site-specific primers for more details. Regardless of where you get tested, please
identify yourself as a healthcare worker providing direct patient care delivery (coded as HCW1 with the BC CDC testing):

- **SPH**: Present to the SPH Emergency Department Triage and identify yourself as a healthcare worker. If you meet the screening criteria below, you will be triaged as a CTAS-2 and will receive a nasopharyngeal swab. You will be called in 24-72 hours with your result and you should self-isolate until you’ve received your result.
- **VGH**: Physicians and residents can present to the Blusson Spinal Cord Center at 818 W10th Ave between 8am-4pm.
- **RCH**: Please liaise with Emma Schon, CMR or Dr. Gerald Da Roza and they will advise regarding which location has the shortest turnaround time.
- **Additional site for Vancouver Community with PHC**: Gravel lot adjacent to Honoria Conway at St. Vincent’s (entrance off 33rd ave), open Mon-Sun 9am-4pm.

At present, all HCW should be getting tested at VCH or PHC sites as the turnaround time is faster. Will update this as FHA gets access to testing on site.

You’ve been tested - now what?

The result times vary from less than a day to up to 72 hours. Once you have been tested, please self-isolate immediately and await for your results. If you are confirmed negative, please continue to self isolate and return to work when your symptoms have resolved or wear a mask to work. If you are confirmed positive, please follow the instructions given to you by Public Health and liaise with your site lead. Different sites have different protocols regarding negative testing prior to returning to work.

Who does not need to be tested?

The following populations do not require testing:

- Individuals with no symptoms or mild symptoms that can be managed at home
- Returning travellers and returning travellers with onset of mild illness within 14 days of return to Canada
- People living in the same household as a patient with respiratory symptoms.

These patients, with or without a history of travel, who have respiratory symptoms that can be managed at home, should self-isolate at home for at least 14 days after onset of respiratory symptoms.

How to test

Recommended sample types for testing COVID-19 are:

- Nasopharyngeal (NP) swab or bronchoalveolar lavage (BAL) for clinically stable patients or outpatients
• NP swab and a lower respiratory specimen (sputum/tracheal aspirate/BAL) for admitted critically ill patients.
Use contact and droplet precautions with a surgical mask and eye protection when collecting a nasopharyngeal or throat swab or sputum

About the Test

• Uses real time (RT) PCR assay based on primers originally published by Chinese scientists and now globally accepted; these give a quantitative result and samples that meet a particular threshold are considered positive

• “Kits” typically include a non-infectious positive control sample and are manufactured by biotechnology companies

• Limitations
  ○ Assay relies upon capturing an adequately deep specimen (must reach nasopharynx), so inadequately obtained specimens may result in false negatives
  ○ Other potential pre-analytical vulnerabilities: handling, transport and storage of swabs, interfering substances, contamination (with other specimens, patients on antiretrovirals)
  ○ Since COVID-19 is a spectrum disease and not a binary disease, patients with a higher viral load (e.g. later vs earlier in disease course) are more likely to test positive
  ○ Other potential analytical vulnerabilities: instrument malfunctioning, active viral recombination, insufficient harmonization of primers
  ○ We do not currently have a clear “gold standard” for which to assess the RT-PCR test’s performance
    ■ There are studies comparing performance of CT based diagnosis vs RT-PCR
    ■ Serological assays (i.e. IgG, IgM) are being developed

• In general, specificity appears to be high

• In general, sensitivity is likely not as great (i.e. not as good of a “rule-out”) 
  ○ CT scans likely have higher sensitivity, particularly earlier in disease course
  ○ Ai et al, 202: In patients with suspected COVID-19 who initially tested negative, repeat NP swab was positive in 23% (15/64) patients
  ○ Bottom line: If suspected to have COVID-19, then treat, isolate and consider re-testing later in disease course
Test results

- **For tested patients**
  The various sites have different mechanisms on how test results are reported. The results are made available either on the respective EMRs or by notification from Public Health. As per the BCCDC, all test results will be reported to the ordering provider. In addition, all positive results will be reported to Public Health for follow-up with employees. Ordering providers can also call for results using the Laboratory Test Results Call Centre 1-877-747-2522. Please do not call the testing laboratory directly, as the staff is focused on providing timely testing. The following are summaries of the current procedures but please refer to the site-specific documents for further details.


  - **SPH:** All samples are being run at the SPH Microbiology Laboratory. For inpatients, POSITIVE results are called to the MRP, negative results will NOT be called, all available under the Microbiology tab on Cerner. The expected turnaround time is 4-6 hours, and they have a new machine running 24h.
  - **VGH:** All samples collected at VCH for influenza/RSV and/or COVID-19 will be forwarded directly to the VGH Microbiology Laboratory. NP swabs and bronchoalveolar lavages will be tested at VGH and all other specimen types will be forwarded to the BCCDC. VGH will be providing testing 3 times daily at 06:00, 12:00 and 16:00, 7 days/week (insert ref #3) The results will be available on PCIS under the Microbiology tab, under special virology testing. If the request is urgent, please call the lab as there have been delays in the posting of results of completed tests.
RCH/BCCDC: At present, testing from Fraser Health Authority is going to the BCCDC lab with a turnaround time of 4-6 days. If there is a positive result on a patient admitted to the ward, Public Health should be notifying the ward though this is not always happening. The results will be uploaded to Meditech though there may be delays. Please add windows log in to the UCI Prov Lab Sign Up so results can be obtained through Meditech. If a test is confirmed positive on the ward, please notify Dr. Da Roza immediately to ensure appropriate contact tracing can be initiated.

Physicians should call the medical microbiologist if the test needs to be expedited or if they have not received test results after 72 hours. BCCDC will not be able to assist patients or physicians calling before the 72 hour timeframe.

- **For tested healthcare workers**
  If you do not receive a call within 24 hours, call 1-833-707-2792 to speak with a nurse to get your results. This line is available 7 days/week from 8:30am - 4:30pm.

BC CDC:  

**References**


III. Personal Protective Equipment (PPE)


Summary

- Viral transmission of COVID-19 from asymptomatic individuals is occurring
- There is a global shortage of vital PPE HOWEVER masks must be changed after each exposure to patient with droplet precautions (suspected or confirmed case)
- For non-aerosol-generating procedures, the appropriate PPE for patient care is:
  - Gloves
  - Gown
  - Medical mask
  - Eye protection (face shield or goggles)
- For aerosol-generating procedures (see below for a list), the appropriate PPE for patient care is:
  - N95
  - Eye protection
  - Gloves
  - Gown
  - Aprons if gowns are not fluid resistant
- CTU members should wear the following at all times when in Emergency Departments
  - VGH: Surgical mask + eye protection
  - SPH: Surgical mask
  - RCH: Surgical mask + eye protection
  - All: change PPE if dirty, damaged, or used for COVID positive or suspected
- All HCWs in Fraser Health Authority are asked to wear surgical masks while at work
• Scrubs:
  ○ Scrubs are being made available for all personnel working in the cohort COVID19 wards and in the ED
  ○ Do NOT take them home - put in laundry hampers after use
  ○ Ideally this will become more widespread as resources increase

Minimizing the need for PPE

• Restrict healthcare worker access to rooms of patients if they are not involved in direct care.
  ○ If you witness misutilization, please speak to the offending individual and if necessary, to someone in leadership
• Bundle activities to minimize the number of times a room is entered (e.g., check vitals during med administration, deliver food while performing other care).
• Hospitals are restricting the number and type of outside visitors

Rational use of PPE

Healthcare workers involved in direct care of COVID-19 patients should use the following PPE:\(^1\):

• Gown
• Gloves
• Medical mask
• Eye protection (goggles or face shield)

For aerosol-generating procedures, use the following PPE:

• N95
• Eye protection
• Gloves
• Gown
• Aprons if gowns are not fluid resistant

N95s have been used for extended periods during prior outbreaks (i.e., wearing the same respirator while caring for multiple patients who have the same diagnosis). Evidence indicates they maintain their effectiveness when used for extended periods HOWEVER the current policies do not recommend doing this at current time. This may change depending on our supplies.

How to don and doff PPE

• [https://www.cdc.gov/hai/pdfs/ppe/ppe-sequence.pdf](https://www.cdc.gov/hai/pdfs/ppe/ppe-sequence.pdf)
• [https://media.phsa.ca/home/iframe?url=BCCA/bccahealth%5cRemovingPPE_20200312](https://media.phsa.ca/home/iframe?url=BCCA/bccahealth%5cRemovingPPE_20200312)
• Note extra hand hygiene step before removing mask/N95
• Feel free to watch colleagues and offer pointers if mistakes are being made; we are in this together
code blue

Code Blue Protocol PPEs

Code blues should be considered as aerosol-generating and use the following PPEs:

**Donning:**
- Tie up hair, wash hands
- Booties extending to mid-calf (optional)
- Gown (disposable preferred; Aprons if gowns are not fluid resistant)
  - Tie with a single knot
- N95 mask with seal check
- Eye protection (face shield preferred)
- Head cover (optional) with a single tie around the neck (have partner double check for open areas)
- Double glove with surgical gloves over the gown
  - If using nitrile long gloves -> one over and one under the gown

**Doffing:**
- Step into ante-room or go to corner of the room farthest away from the patient
- Remove disposable gown from mid section and remove gloves in a single motion (make it into a ball) and discard
  - If nitrile gloves, use alcohol to wash outside of the gloves
- Wash hands
- Remove knot around the head cover and let it drop
- Wash hands
- Remove booties and wash hands
- Remove face shield using the straps behind the head
- Remove N95 one strap at a time, avoid touching outside of mask
- Wash hands

**Future Directions for Code Blue protocol PPEs:**
- Development of code blue PPE carts in anticipation for potential aerosol-generating procedures (CPR, intubation) on the ward to allow for rapid response

**Aerosol-generating procedures**

This is not an exhaustive list of aerosol-generating procedures.

- Nasopharyngeal swab: because it can induce coughing.²
  - The BCCDC and ECDC differ on this point, with BCCDC saying NP swabs can be performed using contact and droplet precautions with procedural mask and eye protection, and do not require the use of an N95 respirator
- Nasopharyngeal aspirates, washes, scoping
- BiPAP and CPAP
● Nebulized therapy
● Opti-Flow
● Intubation,
● Bronchial suctioning
● Bronchoscopy
● Sputum induction
● CPR, especially with bag-mask ventilation
● Autopsies involving respiratory tissues

Priorities for the use of N95 respirators
● Highest priority: healthcare workers performing aerosol-generating procedures.
● N95s can be used for up to 4 hours for multiple patients without removing them, unless it is damaged, soiled, or contaminated (e.g., symptomatic suspected case coughing on you).

Priorities for the use of surgical masks
● Highest priority: symptomatic confirmed cases of COVID-19, followed by suspected cases
● Next highest priority: those caring for COVID-19 patients

Modes of transmission
● SARS-CoV-2 can spread from person-to-person through respiratory droplets in air or deposited on surfaces, and possibly by the fecal-oral route.
● SARS-CoV-2 remained viable in aerosols for at least 3 hours in one study.\(^4\)
● SARS-CoV-2 is more stable on plastics and stainless steel than on copper and cardboard; viable virus was detected up to 72 hours after application to these surfaces.\(^4\)
● Therefore aerosol and fomite transmission of SARS-CoV-2 is plausible.

![Half-Life of Viable Virus](image)

Viral shedding
Over the course of the infection, the virus has been identified in respiratory tract specimens 1-2 days before the onset of symptoms and it can persist for 7-12 days in moderate cases and up to 2 weeks in severe cases.
It should be noted that viral RNA shedding does not directly equate with infectivity.³

**Infection in asymptomatic individuals**

The virus has been detected in asymptomatic persons. On the Diamond Princess cruise ship, where all passengers and staff were tested regardless of symptoms, 51% of laboratory confirmed cases were asymptomatic at the time of a positive test.⁵ In Italy, 6.7% of the laboratory-confirmed cases have been asymptomatic.⁶

**Transmission in pre-symptomatic stage of infection**

Potential transmission from an asymptomatic person has been reported in a familial cluster of five COVID-19 patients hospitalised with fever and respiratory symptoms that had contact before their onset of symptoms with an asymptomatic family member, a young 20-year-old woman, upon her return from Wuhan. She remained asymptomatic for the entire 19 days of laboratory and clinical monitoring.⁷

Pre-symptomatic transmission has been inferred through modelling, with the proportion of pre-symptomatic transmission estimated at 48-62%.⁸ The serial interval (time between successive cases in a chain of transmission, 4.0-4.6 days for COVID-19) is shorter than the main incubation period (5 days), suggesting many secondary transmissions would have already occurred by the time symptomatic cases are detected and isolated.⁹

**References**

IV. Guidelines for ICU/HAU Consultation


While the majority of patients with COVID-19 improve after experiencing mild respiratory symptoms, there are patients who will develop critical illness requiring ICU-level care. These patients may experience complications due to respiratory failure, multiorgan failure, septic shock, or cardiac complications including cardiomyopathy, arrhythmias, and myocarditis.

Guidelines

- Call Critical Care Outreach Team (CCOT) if patient requires 4L NP to keep SpO2>92%
- Call ICU if patient requires 6L NP
- Early involvement of ICU/HAU is KEY
- Avoid aerosolizing measures, including high flow oxygen and BiPAP, if query or confirmed COVID
- Avoid nebulized medications, due to aerosolization, and use MDI only if necessary to maintain supply

Predictors of Poor Outcome

- Age
- Presence of underlying disease (i.e. cardiac comorbidities)\(^2,3\)
- Presence of secondary infection
- Elevated inflammatory markers (elevated CRP, d-dimer)\(^2,3\)

Code Blue Planning

Code Team and Responsibilities

- SPH: Anesthesiology will be called for all intubations of COVID confirmed or suspected cases - responsible for intubation. See SPH specific document for phone number
- Other sites: no specific guidelines in place, please call your code blue team as usual
References

1. Anecdotal reports from Seattle and Italy ICU.


V. Supportive Measures


**Guiding Principle**

The majority of the deaths from COVID-19 are from cardiovascular events secondary to ARDS / respiratory failure.

**General**

- Implement infection control measures immediately in those with symptoms (see Symptoms primer):
  - Droplet and contact precautions for all suspected cases with appropriate isolation
  - PPE for HCP (see PPE primer)
- Obtain nasopharyngeal swabs (see Testing primer)
- Negative pressure rooms generally are not required unless aerosolizing procedures are to be completed, including the following:
  - Non-invasive ventilation (including BiPAP and optiflow / high-flow nasal cannula)
  - Intubation, including manual (bag-mask) ventilation & open endotracheal suctioning
  - CPR
  - Sputum induction
  - Nebulized therapy
  - Airway suctioning
  - High frequency oscillatory ventilation
  - Tracheostomy care

![Figure: Summary of Caring for Critically Ill Patients With COVID-19](image-url)

<table>
<thead>
<tr>
<th>Caring for critically ill patients with COVID-19 is based on the usual management of viral pneumonia with respiratory failure with additional precautions to reduce risk of transmission.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Usual critical care</strong></td>
</tr>
<tr>
<td>Many patients with severe COVID-19 develop acute respiratory distress syndrome (ARDS). Evidence-based guidelines for ARDS in the context of COVID-19 include treatments such as</td>
</tr>
<tr>
<td>- Conservative intravenous fluid strategies</td>
</tr>
<tr>
<td>- Empirical early antibiotics for possible bacterial pneumonia</td>
</tr>
<tr>
<td>- Consideration for early invasive ventilation</td>
</tr>
<tr>
<td>- Lung-protective ventilation strategies</td>
</tr>
<tr>
<td>- Periodic prone positioning during mechanical ventilation</td>
</tr>
<tr>
<td>- Consideration of extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td><strong>Modifications to usual critical care</strong></td>
</tr>
<tr>
<td>- Admission of patients with suspected disease to private rooms when possible</td>
</tr>
<tr>
<td>- Use of medical face masks for symptomatic patients during assessment and transfer</td>
</tr>
<tr>
<td>- Maintain distancing of at least 3 m between patients</td>
</tr>
<tr>
<td>- Caution when using high-flow nasal oxygen or noninvasive ventilation due to risk of dispersion of aerosolized virus in the healthcare environment with poorly fitting masks</td>
</tr>
<tr>
<td>- Clinicians involved with aerosol-generating procedures should use additional airborne precautions including N95 respirators and eye protection</td>
</tr>
<tr>
<td><strong>Facility planning</strong></td>
</tr>
<tr>
<td>- Ensure staff have updated training in infection prevention and control including personal protective equipment</td>
</tr>
<tr>
<td>- Planning at local and regional levels for a potential surge in the need for critical care resources</td>
</tr>
<tr>
<td><strong>COVID-19–specific considerations</strong></td>
</tr>
<tr>
<td>- Antiviral or immunomodulatory therapies are not yet proven effective for treatment of COVID-19. Patients should be asked to participate in clinical trials of supportive or targeted therapies.</td>
</tr>
</tbody>
</table>
○ Bronchoscopy

Monitoring

● Ward: q4h vital signs and PRN
  ○ Early reports describe the possibility of clinical deterioration in the 2nd week of illness, with 25-30% of hospitalized patients requiring intensive support\(^1\)
  ○ Monitor for:
    ■ Arrhythmia (23%), shock (1-10%), ARDS (3-27\%)\(^2,3\)
  ○ Median time between symptom onset and ARDS is 8 days (ACP online)
● ICU: continuous vital signs monitoring with telemetry
  ○ According to JAMA article by Wang et al, in ICU patients:
    ■ ARDS 61% hospitalized cases
    ■ Arrhythmia 44% hospitalized cases
    ■ Shock 31% hospitalized cases

Hypoxemic Respiratory Failure

See Treatment and HAU/ICU Consult primers

● DO: give supplemental O2 by nasal prongs or facemask to target SpO2 > 94% if in respiratory distress, then above 90% once stable\(^4\)
● DO: if full code → early intubation\(^1\) (critical care outreach at 4 L of oxygen, ICU consult at 6 L oxygen)
● AVOID: non-invasive ventilation and high-flow nasal cannula:
  ○ Aerosolizing procedures increase risk of disease transmission
  ○ Associated with high failure rate and need for emergent intubation
  ○ In cases where the patient has concurrent NIV-indicated conditions (e.g., heart failure, COPD) contact the attending physician +/- ICU before initiating
● Medications:
  ○ Empiric antibiotics for CAP & oseltamivir while results pending\(^4\)
  ○ Bronchodilators via MDI with spacer - AVOID using nebulized medications\(^6\)
  ○ No evidence demonstrating benefit of systemic corticosteroids in viral pneumonia; in fact, may be harmful\(^5\)

Care for Patients Not Suitable For Critical Care

● Hold goals of care discussion early, understanding patient’s values and preferences
● Continue medical management as above
● Ensure multidisciplinary approach to address multimorbidity
● Early review of home medications to identify any that may be harmful in context of severe illness and minimize drug-drug interaction
● Involve family members and caregivers in patient-centred decision-making
● If worsening respiratory failure, consult palliative care, initiate comfort measures
Fever and Pain
- Acetaminophen, max 4 g per day unless signs of liver synthesis dysfunction (then 2 g per day)
- Controversy regarding NSAID use in this population
  - AVOID: use for pain fever, as there are other options until evidence more clear
  - For people already on NSAIDs for a good indication, monitor carefully
- No specific guidelines on opioids for pain; prescribe using usual caution in respiratory failure (unless as palliative measure for dyspnea)

Hypotension / Shock
- Fluid resuscitation - conservative IV fluids to minimize risk of worsening hypoxemia
- Reserve IV fluids for hard indications such as hypotension, shock, AKI
  - Hypotonic fluids, starches and albumin should generally be avoided

Hypertension, Heart Failure
- ACE inhibitors/ ARBs: currently, there does not exist any experimental or clinical data to demonstrate beneficial or adverse outcomes with background use of ACE inhibitors
  - Continuation is highly recommended, unless there are other reasons to do so (hypotension, etc) per the HFSA/ACC/AHA.

Intubation & Ventilation Strategies
- Intubation - **airborne precautions**
  - To be done by the COVID Airway Team as per your local institution
    - refer to relevant SPH, VGH, RCH COVID documents
  - Preoxygenation will be key as these patients often have low oxygen reserve and high demand
- Viral pneumonia without ARDS (⅓ of ventilated cases per JAMA Murthy)
- ARDS (⅔ of ventilated cases per JAMA Murthy): acute onset of hypoxemic respiratory failure with bilateral infiltrates
  - Empiric antibiotics for bacterial co-infection until diagnosis is excluded
  - Conservative fluid strategies
  - Lung protective ventilation:
    - Limit tidal volumes starting at 6 mL/kg of ideal body weight
- Limit plateau pressures \( \leq 30 \text{ cm H}_2\text{O} \) (unless there is extrapulmonary restrictive physiology such as obesity, pleural effusions, or abdominal compartment syndrome)
- Permissive hypercapnia
- Optimal titration of PEEP / FiO2 to target \( \text{PaO}_2 \) 55-80 mmHg, \( \text{SpO}_2 \) 88-95%
  - Periodic prone positioning
- If refractory hypoxemia evolves (e.g. \( \text{PaO}_2/\text{FiO}_2 \) ratio \( < 150 \) after attempting all of the above strategies), consider the following additional strategies:
  - Non-conventional modes of ventilation such as APRV
  - Inhaled epoprostenol: Dosing 10 – 50 ng/kg/min. An active humidification system is required to use this therapy.
- Patients who do not demonstrate a physiological response (increase in \( \text{PaO}_2 \) of 20% from baseline) after 30 minutes should be discontinued from inhaled epoprostenol therapy.
- A daily assessment should be performed in an attempt to discontinue inhaled epoprostenol therapy.
  - Consider ECMO

**Arrhythmia, Cardiac Injury**
- Arrhythmia relatively common in the critically ill
- If symptoms of chest pain, palpitations, or dyspnea, OR findings of irregular heart beat:
  - STAT ECG, troponin
- Manage as per ACLS
- Cardiomyopathy with low EF may develop several days after peak of respiratory symptoms

**Hepatitis**
- Mild elevations in transaminases are commonly seen with COVID-19, but fulminant liver failure is not commonly reported
- Severity of ALT and AST elevation correlates with disease severity
- Workup and manage as per usual risk factors

**References & Resources**

VI. PoCUS Guidelines

From the Canadian Internal Medicine Ultrasound Society.

Main message

Minimize the use of POCUS in patients with proven or suspected CoVID infection. Only consider POCUS if it has the possibility to significantly alter care.

Indications for POCUS

- Procedural guidance (particularly thoracentesis)
- To evaluate a possible alternative diagnosis (ie heart failure)
- To avoid the contamination risks associated with a dedicated radiology study

Contraindications for POCUS during COVID pandemic

- Repeat lung POCUS in a known/highly suspected COVID patient to assess progressive hypoxia
- As a diagnostic modality in patients who have already received a definitive test (PCR)
  - Note that there are NO pathognomonic POCUS findings for CoVID
- Educational scans

POCUS providers

- Novice users should NOT be performing POCUS on potential CoVID patients
- If possible, perform POCUS under the supervision of one of the POCUS faculty
Be sure to save all clips (4-6 seconds) for future review with POCUS faculty and for clinical comparison over time.

If there are any questions about the role for POCUS in a CoVID patient, please contact Dr Katie Wiskar (VGH) or Dr Barry Chan (SPH) from 0800-1700.

POCUS machines

- Scans should only be done using dedicated CoVID machines.
- At SPH, this is the CoVID ward machine.
- At VGH, this is the Butterfly (new). Please contact Dr Katie Wiskar (0800-1700) to obtain access to this machine.
- Machine cleaning and infection control
  - Do not bring any extra equipment (towels, gel bottles) into the room
  - Use only single-use gel packets
  - Do not use POCUS in rooms during aerosol-generating procedures
  - For users of the Butterfly: place both the probe and the device (smartphone) in individual sterile probe covers
  - Clean visibly soiled areas before disinfecting
  - Disinfect all surfaces of the machine using Caviwipes. Allow to dry completely before the next use.
  - If no anteroom is available, the device should be disinfected prior to leaving the patient room

VII. Treatment


Standard Treatment

- Please see Spectrum App COVID-19 guidelines (Fraser Health Authority)
- No specific treatments are recommended, many under investigation (see below)
- Supportive care: ensure adequate caloric intake, correct electrolyte imbalances, supplemental oxygen as needed, conservative fluid management if no shock (see above Supportive Measures section)
- Empiric antimicrobial therapy for patients with sepsis or suspected CAP/HAP until bacterial infection ruled out
- Systemic corticosteroids are not recommended and may be harmful
- Use Tylenol preferentially over NSAIDs
- Oseltamivir until influenza is ruled out while seasonal influenza circulates

Therapeutic Agents Under Investigation
1. **Favipiravir**
   - Developed for Ebola but has broad-spectrum activity against influenza, arenavirus, bunyavirus and filovirus\(^1\)
   - **Mechanism of action**: nucleotide analogue that inhibits RNA-dependent RNA polymerase
   - Approved in Japan for influenza
   - **On-going clinical trials**
     - China
     - Phase 2 trial in Thailand

2. **Hydroxychloroquine and Chloroquine**
   Chloroquine is a medication widely used for the past 70 years as an antimalarial as well as anti-inflammatory agent. Hydroxychloroquine is an analogue of chloroquine with lesser drug-drug interaction effects and is widely used for autoimmune diseases such as lupus and rheumatoid arthritis.
   - **Mechanism of Action of chloroquine and hydroxychloroquine**\(^2\)
     - Increases endosomal pH required for virus/cell fusion
     - Interferes with glycosylation of cellular receptors of SARS-CoV
     - Acts on both entry and post-entry stages i.e. antiviral activity observed in vitro, before and after cells were infected with SARS-CoV\(^3,4\)
     - Long known anti-inflammatory property that may synergistically enhance the antiviral property, described above\(^3\)
   - **Indications**\(^6\)
     - Mild COVID - symptoms are mild and no radiographic findings of pneumonia
     - Moderate COVID - symptoms such as cough, fever, and radiographic findings of pneumonia
     - Severe COVID
       - Respiratory Rate>=30 breath/min
       - O2 saturation <=93% at rest state
       - Arterial partial pressure of O2 (PaO2)/oxygen concentration (FiO2) <=300mmHg
       - Patients with 24-48 hour progression of radiographic findings
   - **Doses**
     - Chloroquine 500mg PO BID for first two days then 500mg daily for 5 more days. Handbook for Covid Treatment from Zhejiang University recommends the above\(^6\) dose and advises chloroquine treatment course should not exceed 7 days
     - However, expert consensus from Gunadong Province, published on February 20th, recommends chloroquine 500mg PO BID for 10 days\(^7\)
- Hydroxychloroquine 400mg PO BID on day 1 followed by 200mg PO BID for 4 more days used in China\textsuperscript{4,5}
- Hydroxychloroquine 200mg PO daily for 10 days used in Italy (Lombardy)\textsuperscript{10}
- Consider adding azithromycin for 5 days to increase virological clearance (Gautret et al., \textit{Journal of Antimicrobial Agents}, March 17 2020)

**Evidence:**
- 15 trials have been conducted in 10 Chinese hospitals on efficacy of chloroquine and hydroxychloroquine, ongoing 23 clinical trials in China, no full access to clinical trial data yet, however \textsuperscript{2,10}
- China reported results of >100 patients in these trials have demonstrated that chloroquine is superior to the control treatment in inhibiting the exacerbation of COVID pneumonia, improving radiographic findings, promoting a seronegative conversion, and shortening disease course \textsuperscript{2}
- No severe adverse events were noted in these patients\textsuperscript{2}
- In vitro studies in vero cells derived from kidney cells of African green monkey showed anti-viral activity of both chloroquine and hydroxychloroquine to decrease viral replication in a concentration dependent manner with hydroxychloroquine having more potent antiviral activity over chloroquine\textsuperscript{5}

**Guideline Recommendations:**
- China - the national guideline recommends using chloroquine at 500mg PO BID for mild, moderate, severe cases of COVID for no more than 10 days\textsuperscript{8}
- Netherlands - the Centre of Disease Control (CDC) recommended to offer chloroquine as an option for severe infections that require admission to hospital and oxygen therapy or ICU admission. The recommended dose is 600mg PO X 1 on day 1 followed by 300mg PO at 12h then 300mg PO BID for a total of 2–5 days. The Dutch CDC, however, still recommends supportive management as a reasonable treatment option as well\textsuperscript{10}
- Italy - Italian Society of Infectious and Tropical disease (Lombardy section) also recommends use of chloroquine and hydroxychloroquine in COVID patients with mild respiratory symptoms and comorbidities and COVID patients with severe respiratory failure. They recommend the use of chloroquine 500mg PO BID or hydroxychloroquine 200 mg daily for 10 days, with duration variation of 5 to 20 days based on clinical severity\textsuperscript{10}

**Side Effects:**
- Photosensitivity (reduce by taking at bedtime)
- Nausea, vomiting
- Retinal toxicity (long term use)
- Cardiomyopathy
- Pancytopenia
- Hepatotoxicity
- Extrapyramidal reaction

**Cautionary measures for chloroquine:**
- Monitor for anemia, thrombocytopenia or leukopenia
- Monitor for electrolyte abnormalities
- Monitor for hepatic and renal dysfunction
- Recommended routine ECG to rule out QT prolongation or bradycardia
- Avoid concurrent administration with other QT prolonging medications

**On-going trials**
- Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV). [Trial Link]
- Raoult et al. in France. 24 patients with coronavirus. 75% had repeat negative RT-PCR after hydroxychloroquine 600 mg po daily for 6 days compared to 10% in the control group

3. **Tocilizumab**
   - Actemra (Roche) or Kevzara (Sanofi, Regeneron)
   - Approved by FDA for rheumatoid arthritis
   - **Mechanism of action**
     - Humanized monoclonal antibody
     - Specifically binds soluble and membrane bound IL-6 receptor to inhibit signal transduction and resultant inflammation
     - Cytokine storm may occur with COVID-19 infection, resulting in the release of cytokines, including IL-6, IL-12 and tumour necrosis factor alpha
     - Interfering with IL-6 may be a therapeutic target in severe, critical COVID-19
   - **Indications**
     - Severe COVID-19\(^\text{12}\)
       - Respiratory rate > 30 breaths/minute
       - SpO2 < 93% while breathing room air
       - PaO2/FiO2 < 300 mmHg
     - Critical COVID-19\(^\text{12}\)
       - Respiratory failure requiring mechanical ventilation
       - Shock
       - Combined with other organ failure requiring ICU admission
     - Initial phase with high viral load (afebrile for > 72 hours and/or after at least 7 days after onset of symptoms)\(^\text{13}\)
     - Elevated IL-6 > 40 pg/mL or elevated d-dimer and/or ferritin and/or fibrinogen\(^\text{13}\)
   - **Contraindications**\(^\text{13}\)
     - Age < 18
     - AST/ALT 5 times upper limit of normal
     - Neutrophils < 500 cells/mmc
     - Platelets less than 50,000 cells/mmc
     - Documents sepsis from pathogens other than COVID-19
     - Presence of related comorbidities, according to clinical judgement, to a poor outcome
     - Complicated diverticulitis or intestinal perforation
- Cutaneous infection
- Anti-rejection immunosuppressive therapy
- Caution in pregnancy. There is placental transfer starting at 16 weeks gestation, with higher levels accumulating towards the end of pregnancy

- **Dose**
  - Chinese pilot study\(^\text{12}\)
    - 400 mg intravenously as a single dose. Consider repeating once 8-12 hours after if no clinical response
  - Italian guidelines\(^\text{13}\)
    - If < 30 kg, 8 mg/kg (maximum dose 800 mg) over 60 minutes
    - If > 30 kg, 12 mg/kg over 60 minutes
    - Second infusion 8-12 hours after initial infusion
    - If partial or incomplete clinical response, consider third infusion 16-24 hours after initial infusion
    - After 24 hours from last infusion, repeat IL-6 and/or d-dimer
    - Recommended dose rounding:
      - 50-60 kg: 400 mg
      - 61-85 kg: 600 mg
      - Over 86 kg: 800 mg
  - Dosing adjustments required for hepatic impairment

- **Adverse effects**
  - Increased ALT/AST
  - Neutropenia
  - Thrombocytopenia
  - Injection site reaction
  - Upper respiratory tract infections
  - Nasopharyngitis
  - Headache
  - Hypertension

- **Evidence**
  - A retrospective Chinese pilot study of 21 patients with severe or critical COVID-19\(^\text{12}\)
    - Patients were treated with tocilizumab 400 mg iv once and standard care (lopinavir, methylprednisolone, oxygen therapy)
    - The use of tocilizumab was associated with normalization of fever, improvement in oxygen saturation, improvement in chest CT, normalization of lymphopenia, decreased CRP

- **On-going clinical trials**
  - A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). [Trial Link](#)
  - Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study [Trial Link](#)
4. Remdesivir

- Developed in 2016 to treat Ebola virus
- In 2017, remdesivir was found to have activity against coronavirus family of viruses
- Available for compassionate use from the manufacturer, Gilead (compassionateaccess@gilead.com)

**Mechanism of action**
- Pro-drug of an adenosine triphosphate analog that inhibits RNA polymerase
- By incorporating into RNA, additional nucleotides cannot be added and results in termination of RNA transcription
- Has activity against RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae and Orthocoronavirinae
- Viruses with mutations in RNA polymerase may develop partial resistance

**Dose**
- 200 mg loading dose on day 1 then 100 mg po daily for 9 days
  - This is the dose used in trials for Ebola, and the dose being used in clinical trials

**Evidence**
- In-vitro study showed remdesivir to be active against clinical isolate of SARS-CoV-2 in human cell line
- Case report of patient in the United States with confirmed COVID-19 improving after one day with remdesivir
- Reduces severity of disease, virus replication and damage to lungs in rhesus monkeys infected with MERS-CoV

**On-going clinical trials**
- A list of US clinical trials on remdesivir efficacy and safety in COVID treatment
- A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
- A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment
- A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
- A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoV Respiratory Disease
- A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults [Trial Link]

5. Lopinivir/ritonivir
   - Kaletra (AbbVie)
   - Evidence
     - A randomized controlled trial found no benefit of lopinir-ritonivir compared to standard care in patients with severe COVID-21

Other treatment-related information

1. NSAID use
   - **Recommendation**: NSAIDS may be used with caution in patients without contraindications. Use acetaminophen preferentially over NSAIDs.
   - **Background**
     - Coronaviruses bind to their target cells through ACE2 and ACE2 can be increased by ibuprofen. A letter in *Lancet Respiratory Medicine* by Fang et al. proposed that NSAIDs may worsen COVID-22
     - There is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID-19
     - The WHO does not recommend against the use of NSAIDS23

2. ACEi/ARB use
   - **Recommendation 1**: Patients with hypertension, heart failure or ischemic heart disease should not stop taking ACE inhibitors, ARBS or angiotensin receptor neprilysin inhibitors.
     - There is no clinical data that ACEi and ARB therapy increases the risk of COVID-1924
     - This recommendation is supported by Hypertension Canada26 Canadian Cardiovascular Society27
   - **Background**
     - Coronaviruses bind to target cells through ACE2
     - A letter in *Lancet Respiratory Medicine* by Fang et al. proposed that ACE inhibitors and ARBs could increase the risk for developing severe COVID-19 because ACE2 expression is increased when patients take ACEi or ARBs22
     - There is no clinical data to support the hypothesis that RAAS blockers could increase the ability of the virus to enter the lungs
     - ACE inhibitors and ARBs were shown to upregulate ACE2 in animal studies but upregulation was not seen in limited human studies
● **Recommendation 2**: It is unknown if ACEi and/or ARBs should be started during COVID-19 infection

● **Background**
  - Coronavirus binding to ACE2 leads to downregulation of ACE2
  - ACE2 is responsible for converting angiotensin to angiotensin 1-7, a vasodilator and anti-inflammatory heptapeptide
  - Decreased levels of ACE2 also allows for angiotensin II binding to AT1R, leading to vasoconstriction and increased lung permeability and increased lung injury
  - Elevated ACE2 levels may occur with prolonged ARB use, which may result in blocking excessive angiotensin-mediated AT1R activation and increasing production of angiotensin 1-7 with a COVID-19 infection
  - However, there is no clinical data to support this
  - **Ongoing clinical trial:**
    - Randomized Controlled Trial of Losartan for Patients with COVID-19 Requiring Hospitalization [Trial Link](#)
## POTENTIAL COVID-19 THERAPIES (medicines) IN THE PIPELINE

<table>
<thead>
<tr>
<th>Drug/Therapy</th>
<th>Type</th>
<th>Mode of Action</th>
<th>Data Supporting Use</th>
<th>Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remdesivir</td>
<td>Adenosine nucleotide analogue</td>
<td>Inhibits viral replication</td>
<td>Broad-spectrum antiviral activity effective against SARS &amp; MERS &amp; Human safety trials already done</td>
<td>YES China: ongoing USA: ongoing</td>
</tr>
<tr>
<td>Camostat Mesilate</td>
<td>Protease inhibitor</td>
<td>Blocks enzyme (protease) needed by virus for maturation &amp; entry into cells</td>
<td>Blocked entry of SARS-CoV-2 into lung cells in vitro</td>
<td>NO Approved in Japan to treat pancreatic inflammation</td>
</tr>
<tr>
<td>Lopinavir (LPV) &amp; Ritonavir (RTV)</td>
<td>Protease inhibitor</td>
<td>Blocks enzyme (protease) needed by virus for cellular entry</td>
<td>Effective against SARS-CoV-1 infection both in vitro &amp; in patients Less not effective against MERS</td>
<td>(see below). Approved for use against HIV-1</td>
</tr>
<tr>
<td>Interferon beta (IFN) + LPV/RTV</td>
<td>INFβ alters host inflammatory response to inhibit virus replication</td>
<td>INFβ alters host inflammatory response to inhibit virus replication</td>
<td>Less effective against SARS-CoV-2-SARS CoV-2 in vitro</td>
<td>YES Saudi Arabia: ongoing MIRACLE trial (for use against MERS) China: ongoing against SARS-CoV-2</td>
</tr>
<tr>
<td>Ribavirin + IFN</td>
<td>Guanosine nucleotide analogue</td>
<td>Inhibits viral replication</td>
<td>Broad-spectrum antiviral previously tested against MERS with mixed results</td>
<td>NO Approved for use against RSV and Hepatitis C</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>- Aminoquinidine</td>
<td>Not fully resolved</td>
<td>Inhibits infection of cells by SARS-CoV-2 in vitro</td>
<td>YES China: ongoing Approved to treat prevent malaria</td>
</tr>
<tr>
<td>Acetam (Roche) or Kevzara (Sanofi, Regeneron)</td>
<td>IL-6 inhibitors</td>
<td>Reduced fevers &amp; need for supplemental oxygen for COVID-19 patients</td>
<td></td>
<td>YES China: ongoing Approved in Russia &amp; China for influenza</td>
</tr>
<tr>
<td>Umifenovir</td>
<td>Fusion inhibitor</td>
<td>Inhibits fusion between viral &amp; cellular membranes</td>
<td>Antiviral activity against several other coronaviruses</td>
<td>YES China: ongoing Approved in Russia &amp; China for influenza</td>
</tr>
<tr>
<td>Favipiravir</td>
<td>RNA polymerase inhibitor</td>
<td>Inhibits viral RNA-dependent RNA polymerase</td>
<td>Broad-spectrum antiviral against influenza, aminovirus, bunyavirus &amp; filovirus</td>
<td>YES China: ongoing Approved in Thailand: starting phase 2 Approved in Japan for influenza</td>
</tr>
<tr>
<td>Drug candidates blocking SARS-CoV-2 specific protease</td>
<td>Protease inhibitor</td>
<td>Blocks an enzyme (protease) needed by the virus for infectivity</td>
<td>Because the protease these drugs inhibit is not found in humans, hope for drugs with high potency &amp; low side effects</td>
<td>NO</td>
</tr>
<tr>
<td>SARS-CoV-2 specific antibodies</td>
<td>Antibody</td>
<td>Bind to virus &amp; block infection; bind to infected cells &amp; signal the immune system</td>
<td>Sera from SARS patients inhibits SARS-CoV-2 entry into cells in vitro</td>
<td>NO Labs in Germany &amp; USA working on recovering antibodies from recovered SARS &amp; COVID-19 patients</td>
</tr>
</tbody>
</table>

**REFERENCES:**
1. [https://clinicaltrials.gov/ct2/show/NCT04260705](https://clinicaltrials.gov/ct2/show/NCT04260705)
3. [https://www.bionews.co.uk/content/10.1192/bmj.b3036](https://www.bionews.co.uk/content/10.1192/bmj/b3036)
4. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215080/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215080/)

35
References


### VIII. Supplementary Materials

#### End-of-life Care in COVID

**Symptom management for patients with COVID-19 receiving end-of-life supportive care outside of the ICU**

*per BC Centre for Palliative Care Guidelines*

**BEFORE enacting these recommendations PLEASE clarify patient’s GOALS OF CARE:**

*these recommendations are consistent with MOST-DNR-M1, M2, M3*

**Suggested tools to assist with conversation:**


---

### OPIOIDS

(ALL relieve dyspnea & can be helpful for cough - codeine is not recommended)

Opioids help relieve acute respiratory distress & agitation, contribute to energy conservation

Begin at low end of range for frail elderly

- **MORPHINE**
  - 2.5 - 5 mg PO "OR" 1 - 2 mg SQ q1h PRN (SQ can be q30min PRN), if >6 PRN in 24h, MD to review

- **HYDROMORPHONE**
  - 0.5 - 1 mg PO "OR" 0.25 - 0.5 mg SQ q1h PRN (SQ can be q30min PRN), if >6 PRN in 24h, MD to review

---

### TITRATE UP AS NEEDED

If using >6 PRNs in 24h, consider dosing at q4h REGULARLY (q8h for frail elderly) "and" continue a PRN dose

Also consider (see guidelines*):
- PO solution for cough
  - eg. dextromethorphan, hydrocodone antinauseant eg. metoclopramide SQ laxative eg. PEG / sennosides

---

### Patient already taking opioids

Continue previous opioid, consider increasing by 25%

To manage breakthrough symptoms:
- Start opioid PRN at 10% of total daily (24h) opioid dose
- Give PRN: q1h PRN if PO, q30min if SQ

---

### Patient NOT already taking opioids ("opioid-naive")

- **FOR ALL PATIENTS:**
  - **OTHER MEDICATIONS**
    - Opioids are the mainstay of dyspnea management, these can be helpful adjuvants
  - For associated anxiety:
    - LORAZEPAM
    - 0.5 - 1 mg SL q2h PRN, max 3 PRN / 24h, MD to review if max reached
  - For severe SOB / anxiety:
    - MIDAZOLAM
    - 1 - 4 mg SQ q30min PRN, max 3 PRN / 24h, MD to review if max reached
  - For agitation / restlessness:
    - METHOTRIMETHAPRINE
    - 2.5 - 10 mg PO / SQ q2h PRN, max 3 PRN / 24h, MD to review if max reached

---

### Respiratory secretions / congestion near end-of-life

Advise family & bedside staff: not usually uncomfortable, just noisy, due to patient weakness / not able to clear secretions

- Consider glycopyrolate 0.4 - 0.6mg SQ q4h **OR** atropine 1% (ophthalmic drops) 1 - 2 drops SL q4h PRN

If severe consider furosemide 20mg SQ q2h PRN & monitor response

---

Engage with your team to ensure comfort is the priority as patients approach end of life. Please ensure written orders reflect this. Unmanaged symptoms at time of death will add to distress of patients, family members & bedside staff.

These recommendations are for reference and do not supersede clinical judgement.

Evidence supports that appropriate opioid doses do not hasten death in other conditions like advanced cancer or COPD. Dosing should be reassessed as patient’s condition or goals of care change.

*BC Centre for Palliative Care Symptom Management Guidelines: Dyspnea, Cough*


---

Version: 2020 Mar 18. Recommendations compiled collaboratively by Fraser Health Palliative Care MDs
Hospital Specific Links

1. Royal Columbian Hospital: [RCH COVID Information](#)
2. Vancouver General Hospital: [VGH COVID Information](#)
3. St. Paul's Hospital: [SPH COVID Information](#)